Venus Remedies secures EU GMP renewal from Infarmed, strengthens European market presence
Commitment to stringent European standards reinforces Venus Remedies’ leadership in antibiotics and oncology manufacturing while positioning the company for continued growth in global markets
Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a premier player in the global pharmaceutical industry, has announced the successful renewal of its European Good Manufacturing Practices (EU-GMP) certification by Infarmed, the National Authority of Medicines and Health Products in Portugal. This renewal, applicable to the company's state-of-the-art manufacturing facility for Cephalosporin, Carbapenem, and Oncology (Liquid and Lyophilised Injectable) formulations, not only reaffirms Venus Remedies' commitment to the highest European quality standards but also enhances its growth trajectory within and beyond the European Union.
The company, a market leader in the production of the broad-spectrum antibiotic meropenem, particularly in Italy, has expanded its reach across more than 15 European countries, including key markets like the UK and France. The Infarmed audit, focused on our rigorous quality control systems, validates our ongoing initiatives to deliver superior pharmaceutical products, capable of treating a broad range of severe and drug-resistant infections.
"Since our first EU GMP certification in 2007, we have not only maintained but strengthened our foothold in the European market. This latest certification renewal enables us to leverage our established presence and continue our expansion into new markets. We expect this to significantly contribute to our sales, with anticipated revenues of at least €14 million annually from Europe alone," remarked Mr. Saransh Chaudhary, President of Global Critical Care, Venus Remedies, and CEO of Venus Medicine Research Centre.
With the antibiotics market in Europe projected to grow to USD 10.9 billion by 2023 and the oncology drugs market expected to reach USD 36.95 billion by 2025, Venus Remedies is poised for significant growth. The company's extensive marketing authorisations across Europe reinforce its status as a trusted supplier of high-quality antibiotics and oncology treatments.
Aditi Chaudhary, President of International Business at Venus Remedies, emphasised the strategic importance of this renewal, "This EU-GMP certification is pivotal, ensuring that Venus Remedies continues to provide dependable and effective healthcare solutions across Europe. It positions us to expand our reach not just within the EU, but also into Rest of World (ROW) markets, capitalising on emerging opportunities and fostering growth in regions that demand high-quality pharmaceutical products."
By securing this critical certification, Venus Remedies not only consolidates its role as a key player in the European market but also sets the stage for accelerated global expansion, driving forward its mission to deliver high-quality healthcare solutions worldwide.
Venus Remedies has consistently strengthened its manufacturing capabilities and global exports, demonstrating a strong commitment to advancing high-quality and equitable healthcare. It is one of India’s largest manufacturers and exporters of meropenem—a critical broad-spectrum carbapenem antibiotic used primarily for treating severe or drug-resistant infections. With multiple marketing authorisations across Europe, Venus Remedies has solidified its position as a trusted partner in delivering high-quality antibiotics and oncology products. As the global leader in Italy and holding a significant market share across the EU, Venus Remedies continues to set benchmarks in the pharmaceutical industry, reinforcing its standing as a dependable and influential entity in the global healthcare landscape.
About Venus Remedies
Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 80+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. Its manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by European- GMP, WHO-GMP and Latin American GMP (INVIMA), among others. Ranked 107th in Asia and among the world’s 500 largest pharmaceutical manufacturing companies, Venus Remedies has been granted more than 130 patents worldwide and having more than 75 registered trademarks and more than 15 copyrights for its innovative research products.
Reach out to us at PR Desk
Read more on our Partner sites: Dais World | The Progress Catalyst
Get rewarded for your reading habits on the Dais World app!
